XML 34 R21.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has one operating segment with the goal to discover, develop and commercialize therapeutics (“Therapeutics”). There have been no material changes to the Company's segment structure, the basis of segmentation, or the measurement basis for segment profit or loss or segment assets, compared to those disclosed in Note 14, "Segment Information", to the consolidated financial statements in the Company's 2025 Annual Report on Form 10-K.
The following table presents selected financial information with respect to the Company’s single operating segment for the three months ended March 31, 2026 and 2025 (in thousands):
Therapeutics Segment
Three Months Ended March 31,
20262025
Expenses
External research and development expenses - TV programs, including cost sharing$38,464 $41,987 
Other research and development expenses, including small molecule programs
$23,554 $33,971 
Personnel related research and development expenses
41,828 40,269 
Total research and development expenses103,846 116,227 
Personnel related general and administrative expenses
22,564 18,738 
Other general and administrative expenses
10,947 10,615 
Total general and administrative expenses33,511 29,353 
Segment operating expenses137,357 145,580 
Segment loss from operations(137,357)(145,580)
Segment interest and other income, net8,910 12,610 
Segment net loss
$(128,447)$(132,970)
There is no difference between the segment net loss and total consolidated net loss for the three months ended March 31, 2026 and 2025.